Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles

被引:60
作者
Ali, Hazem [1 ]
Shirode, Amit B. [1 ]
Sylvester, Paul W. [1 ]
Nazzal, Sami [1 ]
机构
[1] Univ Louisiana Monroe, Dept Basic Pharmaceut Sci, Coll Pharm, Monroe, LA 71209 USA
关键词
Nanoparticle; Tocotrienol; Simvastatin; Cancer therapy; Drug delivery; MAMMARY EPITHELIAL-CELLS; DIFFERENTIAL SCANNING CALORIMETRY; GAMMA-TOCOTRIENOL; CANCER-CELLS; MEVALONATE PATHWAY; TUMOR CELLS; STATINS; INHIBITOR; DRUGS; CYTOTOXICITY;
D O I
10.1016/j.ijpharm.2010.01.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Previously it was shown that combined low dose treatment of tocotrienols and statins synergistically inhibited the growth of highly malignant +SA mammary epithelial cells in culture. Therefore, the objective of the present work was to prepare and characterize lipid nanoparticles that combined simvastatin and tocotrienol rich fraction (TRF) as potential anticancer therapy. The entrapment of simvastatin in the oily nanocompartments, which were formed by TRF inclusion into the solid matrix of the nanoparticles, was verified by its high entrapment efficiency and the absence of endothermic or crystalline peaks when blends were analyzed by DSC and PXRD, respectively. The release of simvastatin from the nanoparticles in sink conditions was characterized by an initial burst release of approximately 20% in 10 h followed by a plateau. No significant change in particle size (similar to 100 nm) was observed after storage for six months. The anticancer activity of the nanoparticles was verified in vitro by observing their antiproliferative effects on malignant +SA mammary epithelial cells. The IC50 of the reference alpha-tocopherol nanoparticles was 17.7 mu M whereas the IC50 of the simvastatin/TRF nanoparticles was 0.52 mu M, which confirmed the potency of the combined treatment and its potential in cancer therapy. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:223 / 231
页数:9
相关论文
共 37 条
[1]  
Ahlin P., 1998, ACTA PHARM, V48, P257
[2]   Development and validation of a reversed-phase HPLC method for the simultaneous analysis of simvastatin and tocotrienols in combined dosage forms [J].
Ali, Hazem ;
Nazzal, Sami .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2009, 49 (04) :950-956
[3]   Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering [J].
Bunjes, Heike ;
Unruh, Tobias .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (06) :379-402
[4]   Breast cancer growth prevention by statins [J].
Campbell, Michael J. ;
Esserman, Laura J. ;
Zhou, Yamei ;
Shoemaker, Mark ;
Lobo, Margaret ;
Borman, Elizabeth ;
Baehner, Frederick ;
Kumar, Anjali S. ;
Adduci, Kelly ;
Marx, Corina ;
Petricoin, Emanuel F. ;
Liotta, Lance A. ;
Winters, Mary ;
Benz, Stephen ;
Benz, Christopher C. .
CANCER RESEARCH, 2006, 66 (17) :8707-8714
[5]   Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry [J].
Castelli, F ;
Puglia, C ;
Sarpietro, MG ;
Rizza, L ;
Bonina, F .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 304 (1-2) :231-238
[6]  
DANIELSON KG, 1980, CANCER RES, V40, P1812
[7]   Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization [J].
Dong, Xiaowei ;
Mattingly, Cynthia A. ;
Tseng, Michael ;
Cho, Moo ;
Adams, Val R. ;
Mumper, Russell J. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 72 (01) :9-17
[8]   Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions [J].
Freitas, C ;
Muller, RH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 168 (02) :221-229
[9]   REGULATION OF THE MEVALONATE PATHWAY [J].
GOLDSTEIN, JL ;
BROWN, MS .
NATURE, 1990, 343 (6257) :425-430
[10]   Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer [J].
Graaf, MR ;
Richel, DJ ;
van Noorden, CJF ;
Guchelaar, HJ .
CANCER TREATMENT REVIEWS, 2004, 30 (07) :609-641